Skip to Main Content

Paper Details

TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
Cancer Lett
6
2021
-, MYC, MYC-driven medulloblastoma, Medulloblastoma, TAK228, TORC1, TORC1/2, TORC1/2 kinase, Tumors, c-MYC, carboplatin, glutathione, high, high-, high-MYC, high-MYC medulloblastoma, high-MYC medulloblastoma cell lines, human, human neural stem cell model, mRNA, mTOR, mTORC1/2, malignant pediatric brain tumor, medulloblastoma, medulloblastoma orthotopic xenografts, patients, platinum
Author NameAffiliation
Brad Poore
Pablo TamayoMoores Cancer Center, University of California San Diego, USA Center for Novel Therapeutics
Pablo TamayoMoores Cancer Center, University of California San Diego, USA Center for Novel Therapeutics
Jill P MesirovMoores Cancer Center, University of California San Diego
Jill P MesirovMoores Cancer Center, University of California San Diego
Scott L PomeroyEli and Edythe L. Broad Institute of MIT and Harvard, Boston Children's Hospital, Harvard Medical School
Charles G EberhartUSA Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Charles G EberhartUSA Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Eric H RaabeUSA Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
  • 1 - 9

Datasets

Release 1.2